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The term evidence based medicine (EBM) was first published in 1992, with the term 
defined in 1996 using a definition that is still widely used today: “The conscientious, explicit 
and judicious use of current best evidence about individual patient care.” The practice of EBM 
allows the integration of available evidence from systematic research, specifically clinical 
research, and the best clinical judgment of the clinician(1,2).
EBM is defined as the link between scientific research and good clinical practice(3,4). In 
other words, EBM trials use existing scientific data with good internal and external validity, to 
enforce the results in clinical practice. Evidence in this context is related to the effectiveness, 
efficiency, efficacy and safety of treatment. Effectiveness refers to how treatment functions 
in real-world conditions, efficiency to cheap and affordable treatment for patients, efficacy is 
how the treatment works in conditions of the ideal world, and safety means that an intervention 
is consistent and unlikely to cause any adverse effects(5). A study with high internal validity 
must comply with these characteristics(6).
The concept of stem cell therapy has been advocated for more than 10 years and there 
has been a growing number of clinical reports documenting the use of stem cell therapies in 
humans in particular in respect to myocardial infarction(7-9).
In respect to ophthalmology, several important cell types in the eye have little, if any, 
capacity for endogenous regeneration. As a result the only viable treatment option for patients 
with hereditary disorders that involve the loss of such cells is some type of cell replacement 
therapy. Although the replacement of highly differentiated cells, such as photoreceptors, poses 
challenges, a number of recent experiments suggest that the use of stem cells to achieve this 
goal is now feasible(10).
Distinct stem cell types have been established from embryos and identified in fetal tissues 
and umbilical cord blood as well as in specific niches in many adult mammalian tissues and 
organs such as in the bone marrow, brain, skin, eyes, heart, kidneys, lungs, gastrointestinal 
tract, pancreas, liver, breast, ovaries, and prostate gland(11).
 Stem cell-based therapy has been tested in animal models for several diseases including 
neurodegenerative disorders, such as Parkinson disease, spinal cord injury, and multiple 
sclerosis. Replacing lost neurons which have not been physiologically replaced is pivotal to 
therapeutic success.
Stem-cell therapy has the potential to treat a wide range of retinal diseases. The 
neuroretina is a complex structure whose health depends on blood vessels and retinal pigment 
epithelium (RPE), each of which is affected differently in the spectrum of retinal disease. 
Therefore, three distinct cell types are conceivable targets for future cell therapy in the retina: 
the neuroretina (photoreceptors, bipolar cells, ganglion cells and glial cells), RPE and vascular 
endothelial cells. Depending on the type of retina disease, different cell replacement strategies 
will need to be developed(12).
Degeneration of neural cells in the retina is a hallmark of such widespread ocular diseases 
as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). In these cases the 
loss of photoreceptors that occurs as a primary event (as in RP) or secondary to loss of retinal-
pigment epithelium (in AMD) leads to blindness(11,13,14).
Preclinical studies
Several experimental studies in animals have shown the potential of stem cell use to treat 
retinal disease (Table 1). Routes of administration of the cells frequently used in these studies 
were intravitreal, subretinal (the cells are injected under the retina with vitrectomy surgery) 
and systemic (intravenous injection).
Different types of stem cells such as hematopoietic, mesenchymal, retinal progenitor 
cells, embryonic stem cells and induced pluripotent stem cells were tested(28-32).
Different models of injuries including retinal ischemia induced by increased intraocular 
pressure, the induction of inflammatory lesions in the retina using laser photocoagulation 
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and also models of retinal degeneration using transgenic animals 
were studied(33-36).
These studies demonstrated that stem cells are capable of 
differentiation into some retinal cell types with this capability 
being more limited in adult stem cells.
Thus, when the primary purpose of the study was cell 
replacement, there was a tendency to use cells with the greatest 
differential potential, such as embryonic stem cells, induced 
pluripotent stem cells and retinal progenitor cells. These cells 
have higher differentiation potential but also have higher risk of 
complications, especially embryonic and induced pluripotent stem 
cells including the formation of teratomas, differentiation into tissues 
other than the target organ and rejection (embryonic stem cells).
Mesenchymal stem cells have a reduced ability of cell 
differentiation when compared to embryonic stem cells although 
they may differ in some cells such as retinal pigmented epithelium 
cells and retinal glial cells. However, these cells secrete large 
amounts of trophic factors that could theoretically increase the 
longevity of retinal cells in distress and also to produce a recovery 
of function(29,37,38).
Some studies have shown that, on using transgenic animals 
with retinal degeneration of both eyes, the eye that was treated with 
stem cells preserved much of its morphological structure (assessed 
histologically) and function (assessed by electroretinography) 
compared to the eye that received no stem cells and followed the 
course of degeneration with cellular loss and hence with loss of 
Table 1 - Stem cell use to treat retinal disease in animal models
Study Experimental 
model Route used Type and source of cells Results
Otani et 
al.(15)
Mice with 
retinal 
degenerative 
disease
Intravitreal 
transplantation
Adult bone marrow derived 
lineage-negative hematopoietic 
stem cells
Stem cells (Lin- HSCs) containing endothelial precursors stabilizes and rescues 
retinal blood vessels that would ordinarily degenerate completely, a dramatic 
neurotrophic rescue effect is also observed. Electroretinogram recordings were 
observed in rescued mice at times when they are never observed in control-treated 
or untreated eyes.
Wang et 
al.(16)
Retinitis 
pigmentosa
Systemic Pluripotent bone marrow-derived 
mesenchymal stem cells
Both rod and cone photoreceptors were preserved (5-6 cells thick) at the time when 
control animal had just a single layer of photoreceptors remaining; Visual function 
was significantly preserved compared with controls
Tomita et 
al.(17)
Retinas 
mechanically 
injured using a 
hooked needle
Intravitreal 
transplantation
Stem cell-enriched
bone marrow cells
The stem cell-enriched bone marrow cells had been incorporated and had 
differentiated into retinal neural cells in the injured retina. They had accumulated 
mainly in the outer nuclear layer around the injury sites
Zhang & 
Wang(18)
Light-damaged 
retinal structure
Subretinal 
space
Bone marrow mesenchymal 
stem cells
Apoptotic outer nuclear layer cells were significantly reduced in the bone marrow 
mesenchymal stem cell transplantation group than in the injected phosphate-buffer 
solution group and expressed brain-derived neurotrophic factor
Tomita et 
al.(19)
Rhodopsin 
knockout mice
Intravitreal 
transplantation
Bone marrow-derived
stem cells
This study shows that retinal progenitor cells are likely to be a preferred cell type 
for retinal transplantation studies compared to marrow stromal cells (MSCs). 
However, MSCs may remain an attractive candidate for autologous transplantation.
Meyer et 
al.(20)
Retinal 
degeneration
Intravitreal 
transplantation
Embryonic stem cells Donor cells had been incorporated into most layers of the retina, where they 
resembled retinal neurons in terms of morphology, location in the retina, and 
expression of cell type-specific marker proteins. The presence of transplanted 
donor cells was also accompanied by enhanced survival of host retinal neurons, 
particularly photoreceptors
Siqueira et 
al.(21)
Chorioretinal 
injuries caused 
by laser red 
diode 670N-M
Intravitreal 
transplantation
Bone marrow-derived
stem cells
The sites of retinal laser injury showed greater preservation of the histological 
structure of the stem cell group compared with the control group
Wang et 
al.(22)
Mice with 
laser-induced 
retinal injury
Intravitreal 
transplantation
Bone marrow-derived
stem cells
Bone marrow-derived stem cells (BMSCs) participate in the repair of retinal lesions 
by differentiating into retinal cells. Intravitreal transplantation of BMSCs is a 
potential treatment for laser-induced retinal trauma.
Johnson et 
al.(23)
Glaucoma Intravitreal 
transplantation
Bone marrow-derived 
mesenchymal stem cell
Bone marrow-derived mesenchymal stem cell transplantation resulted in a 
statistically significant increase in overall retinal ganglion cell (RGC) axon survival 
and a significant decrease in the rate of RGC axon loss normalized to cumulative 
intraocular pressure exposure
Castanheira 
et al.(24)
Laser damage Intravitreal 
transplantation
Bone marrow-derived 
mesenchymal stem cell
Grafted cells survived in the retina for at least eight weeks and almost all bone 
marrow-derived mesenchymal stem cell migrated and were incorporated into the 
neural retina, specifically in the outer nuclear layer, inner nuclear layer and ganglion 
cell layer while a subset of grafted cells were found in the subretinal space after 
transplantation.
Lee et al.(25) Developing 
mouse retina
Intravitreal 
transplantation
Bone marrow-derived 
mesenchymal stem cells
The transplanted bone marrow-derived mesenchymal stem cell survived and showed 
morphological differentiation into neural cells and some processes within the host 
retina
Chung et 
al.(26)
Retinotomies 
were made by 
applying an 
Nd:YAG laser 
to rat retina
Systemically 
administered
Bone marrow-derived 
mesenchymal stem cells.
Systemically administered GFP-marked MSCs may be incorporated into 
neuroretinal tissues and play an important role in the wound modulation of 
physically damaged retinal tissues.
Stanke & 
Fischer(27)
Ganglion cells 
were selectively 
damaged
Intravitreal 
transplantation
Embryonic stem cells Embryonic retinal cells promoted the survival of ganglion cells
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retinal function(26,30). Otani et al. demonstrated that, whenever a 
fraction of mouse or human adult bone marrow-derived stem cells 
(Lin-HSCs) containing endothelial precursors stabilizes and rescues 
retinal blood vessels that would ordinarily degenerate completely, a 
dramatic neurotrophic rescue effect is also observed(15,29).
Retinal nuclear layers are preserved in two mouse models of 
retinal degeneration, rd1 and rd10, and detectable, albeit severely 
abnormal, electroretinogram recordings are observed in rescued 
mice at times when they are never observed in control-treated or 
untreated eyes. The normal mouse retina consists predominantly of 
rods, but the rescued cells after treatment with Lin-HSCs are nearly 
all cones. Microarray analysis of rescued retinas demonstrates 
significant upregulation of many anti-apoptotic genes, including 
small heat shock proteins and transcription factors(15,29).
Another important aspect is that these studies demonstrated 
that the intravitreal route for infusion of these cells is a good 
option for rescue therapy with adult stem cells, because there 
is a migration of cells into the retina and also because of the 
growth factors they produce. In the case of cell replacement, the 
technique used was the application of cells in the subretinal space 
(under the central area of the retina called the macula) in order to 
replenish the cells of the retinal pigment epithelium(15,29).
To decrease the possibility of complications arising from 
embryonic stem cells and enable their use in humans, a North 
American company called Advanced Cell Technology has developed 
a technique to differentiate embryonic stem cells into cells of the 
retinal pigment epithelium to be used as cell replacement with the 
injection of these cells in the macular region under the retina.
 In studies in the Royal College of Surgeons (RCS), 
subretinal transplantation of embryonic stem cell-derived retinal 
pigment epithelium in a rat model of deterioration of vision due 
to retinal pigment epithelium dysfunction resulted in extensive 
photoreceptor rescue and improvement in vision without evidence 
of untoward pathological effects. These and other safety studies 
suggest that embryonic stem cells could serve as a potentially safe 
and inexhaustible source of retinal pigment epithelium for the 
efficacious treatment of many retinal degenerative diseases(27-30).
Clinical trials 
Currently there are two lines of research for the treatment 
of retinal disease.
The first is the use of adult stem cells (bone marrow-derived) 
that are administered intravitreally and the other technique is the 
use of embryonic stem cell-derived retinal pigment epithelium 
that are injected into the subretinal space. 
Two case reports have demonstrated the clinical feasibility 
of the intravitreal administration of autologous bone marrow-
derived mononuclear cells (ABMCs) in patients with advanced 
degenerative retinopathies and retinal capillary occlusion(39,40).
Three clinical trials are being conducted in Brazil with the 
use of autologous bone marrow-derived stem cell transplantation 
for the treatment of retinal dystrophy (RP), dry age-related 
macular degeneration and ischemic retinopathy (including 
diabetic retinopathy with macular ischemia). These studies are 
registered with ClinicalTrials.gov, numbers NCT01068561, 
NCT01518127 and NCT01518842(41-43).
The study of the treatment of retinal dystrophy (RP) 
completed the first phase and the data have already been published. 
This was a prospective, phase I, non-randomized, open-label 
study that studied the intravitreal administration of ABMCs in 
three patients with RP and two patients with cone-rod dystrophy 
and an early treatment diabetic retinopathy best-corrected visual 
acuity of 20/200 or worse.
Evaluations such as best-corrected visual acuity, full field 
electroretinography, kinetic visual field (Goldman), fluorescein and 
indocyanine green angiography and optical coherence tomography 
were performed at baseline and at one, seven, 13, 18, 22, and 
40 weeks after intravitreal injection of approximately 1 million 
cells (0.1 mL) into one eye of each patient. No adverse event was 
observed associated with the injection. A one-line improvement 
in best-corrected visual acuity was measured in four patients 
one week after the injection and was maintained throughout the 
follow-up. Three patients had undetectable electroretinography 
responses at all study visits, whereas one patient demonstrated 
residual responses for dark adapted standard flash stimulus (a wave 
amplitude of approximately 35 mV), which remained recordable 
throughout follow-up, and one patient showed a small response (a 
wave amplitude of approximately 20 mV) recordable only at weeks 
seven, 13, 22, and 40. Visual fields showed no reduction (with a 
Goldman Standard V5e stimulus) for any patient at any visit. No 
other changes were observed on optical coherence tomography or 
fluorescein and indocyanine green angiograms. It was concluded 
that the intravitreal injection of ABMCs in eyes with advanced RP 
or cone-rod dystrophy was associated with no detectable structural 
or functional toxicity over a period of 10 months(35,41,44).
The second phase of this study (NCT01560715)(44) and phase
I/II of the protocols of ischemic retinopathy and macular degeneration 
already started and results are expected later this year (2012).
Another line of research is currently under clinical trial 
consists of using embryonic stem cells to treat diseases of the retina.
Schwartz et al.(45) started two prospective clinical studies to 
establish the safety and tolerability of subretinal transplantation 
of embryonic stem cell-derived retinal pigment epithelium in 
patients with Stargardt’s macular dystrophy and dry age-related 
macular degeneration the leading cause of blindness in the 
developed world. Preoperative and postoperative ophthalmic 
examinations included visual acuity, fluorescein angiography, 
optical coherence tomography, and visual field testing. 
These studies are registered with ClinicalTrials.gov, numbers 
NCT01345006 and NCT01344993(46).
 After surgery, structural evidence confirmed cells had 
attached and continued to persist during the study. The authors 
did not identify signs of hyperproliferation, abnormal growth or 
immune-mediated rejection in either patient during the first four 
months. Although there is little agreement between investigators 
on visual endpoints in patients with low vision, it is encouraging 
that during the observation period neither patient lost vision. 
Best-corrected visual acuity improved from hand motions to 
20/800 [and improved from 0 to 5 letters on the Early Treatment 
Diabetic Retinopathy Study (ETDRS) visual acuity chart] in the 
study eye of the patient with Stargardt’s macular dystrophy, and 
vision also seemed to improve in the patient with dry age-related 
macular degeneration (from 21 ETDRS letters to 28).
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They concluded that embryonic stem cell-derived retinal 
pigment epithelium cells showed no signs of hyperproliferation, 
tumorigenicity, ectopic tissue formation, or apparent rejection 
after four months(46).
There are different systems to evaluate the level of scientific 
evidence for the clinical use of a therapeutic procedure.
In this article, I found the system used at the Oxford Centre 
for Evidence-based Medicine the best(44-48).
Conclusion
Stem cell therapy for the treatment of retinal diseases still has 
a low level of evidence for clinical use. Pre-clinical studies were 
consistent and evaluated the behavior of different types of stem 
cells injected via three routes (intravitreal, subretinal and systemic).
Different models of retinal injuries were tested and the 
results were evaluated according to anatomic and functional 
characteristics. With these data we would consider a level of 
evidence 5 according to Oxford Centre for EBM. With respect to 
the clinical trials that are currently underway (Phase I/II), they are 
non-randomized prospective studies with small sample sizes and 
therefore on completion, they will provide a level of evidence of 
1B according to the Oxford Centre for EBM.
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